Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Devyser Diagnostics, Audiocast with teleconference, Q2'24

By Inderes7/23/2024, 7:00 AM
Devyser Diagnostics

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Fredrik Alpsten
00:00 - 03:00

Again, welcome to Devyser. Q2 2024 Earnings Call. It's a great pleasure to have you all here. This is the first time we've published our Q2 results in July, earlier than the end of August. And that's something I'm very proud of. Today, you will listen to me, Fredrik Alpsten, the CEO of Devyser, and Theis Kipling, our Chief Commercial Officer responsible for business development. I have also asked our CFO, Sabina Baylin, to join us during the Q&A session. A lot of positive things are happening in the company. Those of you who follow us more closely may have seen a record number of positive press releases during the quarter. The sales from bond tenders, etc., mentioned in these published press releases are not yet reflected in the Q2 numbers. You will see that later today as we embark on a journey through our Q2 results. The second part of the presentation will be dedicated to highlighting the key achievements from the quarter and discussing our commercial outlook. Sales developed very well during the quarter and amounted to 53.2 million SEK, a new record. The previous record from last year was 50.7 million SEK. Sales growth compared with the same quarter last year was 41% in SEK and plus 40% in local currency. All growth is organic. The growth of plus 40% in local currency is the highest growth we have seen for one single quarter since the company was listed. The growth for the first six months of 2024 was 35% in SEK and 34% in local currency. The growth for the last 12 months was 38%. With our innovative products, high market growth, well-suited commercial organizations that we have heavily invested in over the last quarters, and some of the best commercial partners. We are confident that our current positive sales trend will not only continue, but also strengthen even further. While we may face individual quarters that do not perform as well, The overall trend is clear. Our sales are on a significant upward trajectory, with most quarters expected to be record-breaking. Even with the impressive sales growth we have achieved in the first six months. We are confident that we can maintain this level of growth in the second half of the year, achieving at least the same growth in local currency as we did in the first half of the year.

Unknown 1
03:01 - 03:03

Okay, you have hit that at the heart of it.

Fredrik Alpsten
03:07 - 10:01

It's always dangerous to look at single quarters and draw too many conclusions from them. A single order can heavily affect a quarter. It's much better to examine rolling 12-month periods. EMEA grew by 32% compared with the previous 12 months. During the quarter, we saw high sales growth in the Middle East. The European markets, although not fully satisfying, showed growth, and the Asia Pacific region grew by 26% compared with the previous 12 months. Q2 grew by 75% compared with the same quarter last year. During the last 12 to 18 months. We have signed up quite a few new distributors in Asia, and some of them have now started to generate revenue. The growth in North and South America was plus 166% compared with the previous 12 months. We are very optimistic about North America despite the flat development during the quarter. During the last quarter, there were uneven purchasing patterns from one of our distributors. And please remember that we do not yet have that many customers in North America. The potential in North America is massive, and we have just started to penetrate this huge market. North America will be one of our top priorities for the near, mid, and long term. Our direct sales represented about 75%, and our distributor sales represented about 25% of total revenue, both for the quarter and for the last 12 months. However, as sales through Thermo Fisher are increasing and new distributors in regions like Asia and the Middle East are added, we may see an increased share of distributor revenue. One of the device's strengths is its business model. We have very high gross margins because we sell only consumables and software, not new equipment. Since I joined Devyser in the fall of 2020, we have managed to increase the gross margin from around 75% to around 85%. The reason is a scalable production process, which has until now been rather manual. and our ability to increase prices. However, as we had outgrown our production facility, we decided in spring 2023 to move to a bigger facility to enable higher production volumes and to automate the production processes. He has signed a seven-year lease with an option for another four years. With one shift of production, we can stay here even if we have growth of an average 50% per year. We got access to the new facility in January this year and moved our offices to the new facility in February. During the spring, we have worked extensively to build up the production and R&D part of the facility. As with all certified and regulated businesses, this must be done by the book, documented, validated, and verified. It must be approved by the regulatory authorities and notified bodies when ready. The regulatory authorities have now approved the new production facility, and we can move production and R&D labs from the old facility to the new one during Q3. All work to finalize the new facility has been costly. Cost of goods sold was negatively impacted by 3 million SEK during the quarter. We also had a negative impact. We also expect a negative impact during the third quarter, but we anticipate being back on track by the end of Q4 this year, with a gross margin in excess of 80%. This investment will help us drive down production costs even further and continue automating the production processes, thereby increasing our gross margins in the long run. It should also be mentioned that to minimize risk, we decided to rent both facilities, the new one and the old one, throughout the entire year of 2024. This means that when we enter 2025, we will not be paying rent for the old facility. The quarter's EBIT was in line with our expectations. It amounted to -23 million MSEK, compared with -14 million MSEK in the same quarter last year. A couple of one-time items caused a slight increase in expenses. The move to the new premises, as explained earlier, incurred some 3 million extra during the quarter. Double rent for both the new and old premises. We have added 3 million MSEK in additional rent costs per quarter during 2024. We also increased costs for our expansion in North America, which included, among other things, work to secure the best possible compensation for our products, as well as efforts to set up our own warehouse in the US. Another three million MSEK were incurred. The positive development of Devyser's share price also meant that during the quarter we experienced higher costs for our incentive programs, with the total cost for incentive programs amounting to 2 million MSEK. It should also be noted that during the second quarter of 2023, we reversed a provision of 2 million MSEK for a so-called retroactive payback fee. We are convinced that the positive earnings development we saw in 2023 will continue, and that we will achieve our financial goal of an EBIT margin exceeding 20% from 2024 to 2026. Devyser has a very strong financial position, with 201 million in cash at the end of the quarter and no interest-bearing debts. During the quarter, an employee warranty program expired and the options were exercised. This resulted in a capital injection of approximately 17 million MSEK for the company at the end of the quarter. With that, I hand over to Theis Kipling to give some highlights from the portal and provide a commercial outlook.

Theis Kipling
10:03 - 20:27

Thank you, Fredrik. Indeed, Q2 was a record quarter, and I'm pleased to guide you through some of the updates and the outlook to give you the gist and the understanding that, in fact, we're just getting started on embarking on new endeavors starting June 17th. If you turn to the next lone tone, we announced that we have expanded the agreement with Thermo Fisher to now cover global territory. We initially hesitated to give Thermo Fisher access to global territory for our transplantation products a year ago when we first signed the agreement with them, because we wanted to ensure that customers responded positively to the collaboration and confirm the investments and dedication made by Thermo Fisher. We have now seen positive responses and hence are now working with them to build significant global success. Our products have long been advocated for by key opinion leaders, and we are now seeing laboratories begin incorporating these products into their clinical routines across both Europe and North America. We are confident that this momentum will only increase once we onboard users from Asia-Pacific as well. Granting Thermo Fisher access to our global markets is strategically beneficial for the revenue growth of Devyser, as we can now expand our market reach by an additional 43%, measured by the number of kidney transplants in the Asia Pacific region. Together with Thermo Fisher, we are targeting a market worth over 1 billion US dollars and have already made significant progress in establishing new market standards using the Devyser One Lambda post-transplantation products. We have already achieved the first IVDR approvals for both our assays and software. We are actively seeking FDA approval in the US and are on a solid path towards also having our tests reimbursed in our CLIA-certified laboratory. You can move to the next slide, focusing on the revenue logic related to our global partnership. This equally helps with cost synergies. Since we no longer need to maintain a product line exclusively for transportation products, including taking them through regulatory approvals, etc., these efforts will now be focused solely on the Thermo Fisher co-branded product line. Hence, this is truly a sound business decision. As we now look into year two and onwards. Together with Thermo Fisher, we are intrigued by the opportunities ahead, not least in the product pipeline front where we have several new and potentially groundbreaking product launches coming up. While these products are not automatically included in the master agreement we have with Thermo Fisher, we do believe that these products will significantly enhance both Thermo Fisher's and our position within the transportation sector for the years to come. Let's move to Italy during Q2. We closed deals worth 84 million Swedish kronor in Italy, including an all-time high tender covering the region of Tuscany. We continued the expansion of our oncology business as well, as we won another deal for our telomere product. If you add the announcement that we made late last week, that number is close to 90 million Swedish kronor in the past 3 to 4 months. Italy remains our largest market, and I'm thrilled to see how the team continues to take market share and expand our business. Looking ahead, I'm excited to see that we still have a large number of opportunities to further accelerate this momentum. I'm sure that a lot more will come. Focusing on Thalassemia, which is one of the most prevalent hereditary diseases in the world. The market is therefore huge, and Devyser is well positioned. We are well positioned with our product, which grew almost 60% during the first half of this year compared to the same period last year, and now accounts for about 10% of our total sales. We're pursuing a large number of opportunities in markets where the prevalence of Thalassemia is high, such as Italy, Spain, Saudi Arabia, Malaysia, India, and Singapore, and I could go on. Recently, our smear test was chosen for a state screening program in California, US, and we are pursuing other similar state programs within the US as well. Lastly, I can share that we are in dialogue with large pharmaceutical companies who have expressed interest in the product as well, and I will soon come back with more information about these potential engagements in the months ahead. Another interesting product is our test, where we have seen a lot of strong traction. We continue to expand our market position, and we just signed up with another leading laboratory in Canada in addition to Hymer, Quebec, which we had previously announced. In addition, we announced in December that our RC test was chosen for nationwide screening in Wales, adding yet another country to the list where our test is chosen for either state, regional, or nationwide screening. One of the markets yet to be penetrated for testing is the US. Where is the market standard still the prophylactic injection for pregnant women? However, just recently the prophylactic drug program experienced a shortage by the suppliers, and thus we now are seeing a significant uptake of requests for testing in the US. I have been very bullish about our market opportunity for this product in the US, and now, especially since the market is turning towards testing before injection, I am even more optimistic about its potential. These days, we are in dialogue with some of the largest laboratory chains and laboratories in the US concerning our RHD tests, and I'm hopeful that one or several of these opportunities will materialize during this year. I'm excited to be communicating soon about this. Let's move into our next update, regarding what the future holds with Thermo Fisher. We are now one year in, and we're already seeing strong growth, currently up some 65% above H2 2023 with lead times, as we have previously discussed, ranging from 12 to 18 months. We are just at the beginning of our growth journey with Thermo Fisher, and we are confident that this partnership will accelerate in the months and years to come. We're adding three new indications: heart, liver, and lung. We're pursuing FDA clearance and launching groundbreaking new products for the care of transplantation patients globally. These additional three indications will expand our addressable market measured by the total number of transplantations performed globally, as mentioned earlier. This is an exhilarating time in the field of transplantation, and I'm absolutely sure that Devyser will become a key player for many years within this dynamic area. Looking at what's next in the U.S., we continue to capitalize on the opportunities within testing for cystic fibrosis following updated guidelines from the previous year. Our first customer is soon transitioning to clinical routine, and more opportunities are already in the pipeline. RHD, as mentioned, looks very promising, and I'm confident that this will be an excellent product for the U.S. market in the upcoming years. Additionally, we are gaining traction in Canada. This product has the potential to become one of our best-selling products in the company. In the U.S., 15% of the population is RHD negative, meaning that, across the 3.7 million new births annually, there's a patient population of 550,000 patients annually who should be tested for their fetal status, representing a significant opportunity for Devyser. Now, with the growing interest in RHD testing rather than defaulting to the prophylactic treatment device, we see new opportunities emerging. Genomic Laboratories, our CLIA-certified laboratory in Atlanta, is performing well. We are on track towards having our first products reimbursed and covered, as well as our engagement with the UK-based oncology company, furthering our collaboration. it is progressing well and the laboratory is fulfilling its objectives as a growth catalyst for Devyser within just a few years in the U.S. I'm confident that our business in North America will become the largest region for us, even surpassing our otherwise large and strongly performing market in Italy. With that, I hand it back to you.

Fredrik Alpsten
20:33 - 21:39

Thank you, Theis. As you know, over the last two years we have taken some important steps to build a global, fast-growing, highly profitable diagnostic company. As we have also heard, we are very optimistic about the future. We are focusing on expanding in North America and Europe. That's where they are. through all our sales channels, direct sales partners, our CLIA-certified laboratory, and distributors with our innovative products, high market growth, and well-suited commercial organization that we have heavily invested in over the past quarters, alongside some of the best commercial partners. We are confident that the historical development we have witnessed can continue and even accelerate. However, as important as high growth is to sustain, our path to profitability remains our main focus. With that, we conclude our presentation now and open the floor for questions, back to the operator.

Operator
21:40 - 22:06

If you wish to ask a question, please dial the pound key and then five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Ulrich Ratner from Carnegie. Welcome everyone to the quarterly earnings call for Devyser for the second quarter of 2024.

Ulrich Ratner
22:08 - 22:54

Thank you very much. Good morning, very concise. Uh, I have a few questions on my end. First of all, I am very thankful for the split in one-offs. Uh, but perhaps if you can comment on how these numbers have developed since Q1. I note that operating expenses (opex) have increased close to 10 million, and it appears, at least in the reported numbers, to be mainly in administration and R&D. So if you can help us understand that dynamic, how much is related to increased one-offs, and what to extrapolate and what not to extrapolate into the second half of the year. That would be your first question, please.

Fredrik Alpsten
22:54 - 24:24

Yes, without going into too much detail, because I'm not fully aware of them, I think it's important to remember a couple of things. The setup of the new production facility. The cost for that and the move has affected the cost of goods sold by 3 million during Q2. The extra cost we have for having two facilities. The exact cost for those facilities is taken as administrative costs, not affecting the cost of goods sold. So that's one of the reasons why administrative costs have increased significantly. And then we talked about the nice share price development. We have seen quite a bit. Also, regarding administrative costs, when it comes to R&D expenses, you have both capitalized and non-capitalized R&D expenses. We may have capitalized slightly less during the quarter due to accounting reasons. I'm quite sure that if you take both the capitalized and non-capitalizd costs, they have not increased that much compared with Q2. I think we'll be back on track regarding how much we capitalize in Q3 and Q4. Does it answer your question?

Ulrich Ratner
24:24 - 25:24

It does. And, really strong sales development across the board. Um, and you touched upon the size, and you talked about expected continued sales development for Thermo Fisher Scientific into the second half of the year. I know that you have historically commented, and continue to comment on, the lead time of 12 to 18 months in regards to the ten-year activity. But in terms of the actual tender activity, have you seen any type of acceleration or interest in your asset portfolio? And a follow-up question would be, you mentioned that you're now ready to commercially launch the expanded assay portfolio. Are these already commercially available, or when are you expecting the first revenue to come into the company?

Theis Kipling
25:26 - 26:29

Thank you. Let's start with the first one. I mean, the traction that we're seeing is still in the early phase, I would say. So, of course, we are still only just a year in from the initial launch with Thermo Fisher. And still with that, I think we are sure with the initial traction we are seeing, what really reassures me is when you look into what is being published, what the clinical research that is being made out there. And that's pretty phenomenal. I'd say, talking to the opportunities that we have with our products. So, short answer or to make that short as possible, we're still in the early phase, but we are very confident and reassured by the initial traction in terms of revenues, customer interest, and tenders that are being written. So, a very strong start. But that should bode well for what the future should hold for us and Thermo Fisher together.

Fredrik Alpsten
26:31 - 27:15

Great. Yes. The reminder there, Ulrik, is to remember that we signed the agreement with Thermo Fisher at the beginning of Q2, but they didn't launch until the end of Q3. So we are still in quite an early phase. We have not been with them for 12 months yet. They have not launched their products for 12 months. And as we said in the interim report, we foresee revenue from the expanded territory starting from 2025. Even though we have some ongoing discussions for some certain accounts in these countries, you should not expect too high revenue for the expanded in 2024. Please wait for 2025. Okay, great.

Ulrich Ratner
27:15 - 27:23

The second question related to the timing of when the expanded number of accept tests were to be commercially available in the US.

Theis Kipling
27:24 - 28:02

Yeah. So as Metric also commented, I think we are expecting to see most of the initial onset of that during 2025. And for that, obviously, there are a number of adoption aspects that are being made now with customers. But again, lots of great traction also on those new indications that are being made on customer sites today, especially in the US and Europe. So there will be a lot of that, and you'll read about and see during the remainder of the year. And that will kick off the revenues for 2027 on those new indications.

Unknown 2
28:03 - 28:03

Okay.

Ulrich Ratner
28:03 - 28:55

Great. And obviously the Thermo Fisher collaboration has expanded, both in terms of products and geographies. But in general, it looks like your products have commercial traction in the US, and you have a portfolio beyond the transplantation portfolio, yet you still only have three people in terms of your headcount in the US; obviously, you have your CLIA lab, but wouldn't it make any sense in your view to expand the number of distributors selling your product portfolio in the market? Breaking it up by indication like cystic fibrosis or RHD screening, or would it make more sense for you to keep it in-house and just go for potentially more high-value tenders?

Theis Kipling
28:57 - 29:54

Good question. And something where we are actively assessing, day by day, as these opportunities come by. We have been approached several times by some very significant, potential partners and decided that we were better suited to deliver on these opportunities ourselves. That being said, we are constantly in dialogue with very attractive opportunities that could make us pivot a little bit. And obviously, the reason we currently have only three in the field organization in the US is because we are careful in terms of investments. And we remain very confident about the opportunities. So when those opportunities turn, you'll see that we will be investing in an increased fashion in the US, but for the time being, we're confident with the level that we have versus the potential that is coming ahead of us.

Ulrich Ratner
29:57 - 30:35

Great. Some additional questions on the general commercial activities, and potentially we could keep our eyes on the US and on the lab. So internally in your lab, what is your current commercial traction? How are things progressing and what type of revenues are you expecting prior to obtaining reimbursement in the US? And I heard throughout the call that you have invested in people specializing in the matter of obtaining reimbursement. So where are we at in that process?

Theis Kipling
30:36 - 32:05

We are probably looking at reimbursement if we just look at that. The initial products that we have commercialized are tests. And now we are seeking reimbursement for our cameras and our cfDNA assays. So the two transplant products and those two products are not covered by the Thermo Fisher Agreement. We have retained exclusive rights to commercialize those through our laboratory. And those are the efforts we are now investing in, in terms of getting those covered by and reimbursed in the US. Timelines can be a little bit unclear, but we're hoping that early next year, you would see that we have those products covered and then we will see volumes quickly start to be generated. In addition to that, there are a number of opportunities for adding new products. One of the products, we are currently working on the test for cystic fibrosis, as well as test facility media. And then there could naturally be additional products, but it could also be additional partnerships like the one we have with Thermo Fisher Scientific, generating up to 25 million Swedish kronor. Just that one opportunity. So it is meant to be a widespread and focused catalyst for growth in the US. And it's shown to be also great.

Ulrich Ratner
32:05 - 32:32

And my last question, which is also a follow-up question: If you could talk a little bit about the phasing of revenue in the second half. We already talked about Thermo Fisher, but if we could discuss the delivery of the already awarded RHD tender in Canada as well as the cited commercial contract. How should we look at this for the second half of the year?

Fredrik Alpsten
32:33 - 33:26

Maybe I can say a couple of words there. It's always difficult to talk about single quarters because it can be delayed by the customer. What we said and what I said earlier is that we are rather confident we can maintain the same growth during the second part of 2024 that we had during the first quarter. First, the first six months of 2024. And that's in local currency. As you know, we experienced growth of 34% for the first six months. So we are confident that we can maintain at least the same during the second half of the year. I think we prefer not to comment on single quarters because there can always be, uh, delays. But if you look at two quarters, it's easier to discuss things.

Ulrich Ratner
33:28 - 33:43

Okay. But do you expect some deliveries in the contracts and RHD screening awarded already in Canada during the second half of the year, or is there a risk that this will be pushed into 2025?

Theis Kipling
33:45 - 33:46

Maybe I did.

Fredrik Alpsten
33:47 - 33:49

Sorry, sorry. I'll see you soon.

Theis Kipling
33:50 - 34:48

So, uh, you're right. Exciting, isn't it? The vast majority will happen in 2025, right? But that would also mean that we are. We're starting to see the ramp-up of volumes and revenues here during the second half. But the bulk of that potential kicks in in 2025 with regard to road testing in Canada. That too is more of a 2025 opportunity. There have been some delays with Quebec, as we have already communicated. But as I also mentioned in my walkthrough of the commercial update, we just landed another account there, and I'm still waiting for some details before I can disclose much more, but I wouldn't expect that would have a great impact in 2024. But it's going to be building on our accumulation of growth in 2025 and beyond.

Ulrich Ratner
34:51 - 34:56

All right. That was all the questions on my end. Thank you very much.

Unknown 2
34:58 - 34:59

Thank you.

Operator
35:00 - 35:05

The next question comes from Oskar Bergman from Redeye. Please go ahead.

Fredrik Alpsten
35:07 - 35:08

Hi, guys. I just have.

Oskar Bergman
35:08 - 35:27

A few questions for you. I was looking at the number of employees, and it has gone up quite a bit since Q2 of last year. If you could provide some commentary on your organizational increase. Well, I guess, increase.

Unknown 2
35:28 - 35:29

Yeah.

Fredrik Alpsten
35:29 - 36:12

If you look back one year, of course, it has increased significantly. But if you look at Q1, it has not done that. We have invested quite heavily in the supply chain because we are building up for future growth. We have also invested quite heavily in our commercial organization. So those are the two main drivers I would say. We have added some special competencies. We have already talked about reimbursement and market access in the US. So that's the kind of expertise that we have hired. We do not, however, expect to have any substantial more hires during the remainder of the year.

Unknown 2
36:13 - 36:13

Okay.

Oskar Bergman
36:14 - 36:22

And, uh, could you just give an update on the clear lab? Uh, in terms of it running on a profit?

Fredrik Alpsten
36:24 - 37:12

No, it's not yet running on a profit. I think we shared at the last earnings call that we expect positive numbers during the second part of the year. Uh, and we just thought that that part of the SVA is still around with a loss. But it's not a huge loss. We have four or five people in the lab now, and we have started to work both with cited and other things that we have disclosed here. We have some ongoing discussions. The other new ventures, they have not started to generate revenue yet, but we are optimistic that they will. We will do that during this year. So we remain with what we said earlier. Positive during the second part of the year.

Oskar Bergman
37:13 - 37:34

All right. Thanks. And my, my. My next question is a bit speculative and I guess you can't really tell. Uh, so far. But, um, despite that, they do stand a good chance of being renewed. And if it is renewed, should we expect similar sales figures going forward, or could it be even greater?

Fredrik Alpsten
37:37 - 37:50

Maybe it's a question to you guys, but please also remember we cannot just disclose what has been discussed between a partner and us from the office. But maybe you can give some more color here. Uh, Tyson.

Unknown 2
37:51 - 37:51

Yeah.

Theis Kipling
37:51 - 38:25

I mean, right now the agreement covers two years, right? So, $2425. I'm back in the States in mid-August, both in California and in the lab when we're together. Which side? Actually, I'm in the lab. However, it's too early to be communicating. Uh, more than just that. But it's moving along. Both parties are very satisfied with the engagement.

Unknown 2
38:26 - 38:26

Welcome to the Devyser earnings call for the second quarter of 2024.

Oskar Bergman
38:26 - 38:51

And just a final question then on the Thermo Fisher deal. I understand the lead time of 12 to 18 months from the initial signing before we can see any considerable sales developments. But apart from this, are there any other bottlenecks that we should be aware of that could hinder sales from growing?

Theis Kipling
38:53 - 39:46

On my side, I think that's the natural lead time. Right, which is what we are. We are in. But beyond that, what really excites me about these opportunities is how we're also changing the way transplant patients are cared for. Right. And, uh, here especially how we can protect the organ from being rejected. We are also working on building up a lot of evidence for why monitoring is important. Um, and that also. It takes some time, but if you call upon some of the key opinion leaders, you will hear that what we currently have is very exciting and could be game changing in the way of caring for transplantation patients. So that's why we.

Unknown 2
39:46 - 39:47

Are.

Theis Kipling
39:47 - 39:57

Super excited about what's to come. And we're very confident that it will come. It just takes the natural time. This doesn't happen overnight.

Oskar Bergman
39:58 - 40:01

Yes, thank you. That will be all for me.

Fredrik Alpsten
40:03 - 40:04

Thank you, Oscar.

Operator
40:09 - 40:14

The next question comes from Ludwig Lundgren from Nordica. Welcome, everyone, to our second-quarter earnings call for Devyser.

Ludwig Lundgren
40:15 - 40:31

Hi, Fredrik. So, regarding the EMEA countries, we are currently establishing direct sales channels in Germany, Spain, and France. How has the development been here? Have the dynamics been similar to when you established direct sales in Italy?

Theis Kipling
40:35 - 40:36

Did I cover that one further? Yeah.

Fredrik Alpsten
40:36 - 40:37

Please. Please.

Theis Kipling
40:37 - 41:52

Yes, I mean it replicates in general. You might recall from earlier calls that when we first started going direct in regions like the DACH region, Barnardo's UK, and so forth, the growth curve looks similar. That being said, as we also noted in the report, we had expected more growth in the direct markets of Europe. However, I am very reassured that this growth will absolutely come. We are posting around 30%, actually 34%, in the direct markets and we're expecting over 50% growth in some of those markets. We aim to see a doubling of these figures. So, we're working on achieving that. But again, when I look at what we've accomplished in larger markets like the DACH region and our network reach, it looks very solid. And now we are doing the same in France. We're replicating the approach in Spain and the UK, which are a bit later on the growth curve that we are developing. So, I'm confident these markets will also replicate what we have achieved in Italy.

Ludwig Lundgren
41:54 - 42:12

All right. Great. Thanks. However, when you switch to direct sales, you get a price effect. Right? But would you say that this typically also drives volumes, such as in these new markets where volumes increase when you establish direct sales channels?

Theis Kipling
42:14 - 42:33

Yes, usually that should happen. Initially, the effect is obviously on the price side where you move from a distributor model to a direct sales model, adding incremental value. As you get closer to customers and build relationships, particularly through tenders, volumes also start to increase, which we confirm when analyzing our numbers.

Ludwig Lundgren
42:35 - 42:52

All right. Great. And just a final question on pharmaceutical companies' interest that you mentioned regarding the smear test: is a potential use of the test as a companion diagnostic or are there other applications for the tests?

Theis Kipling
42:53 - 43:20

That's too early to comment on, but it's a market and companies working within sickle cell disease and thalassemia that I would encourage you to explore. It's very interesting. And we have one of the best products out there; I'm confident. So, I think we are very well suited to partner with and be a strong ally to pharmaceutical companies.

Ludwig Lundgren
43:23 - 43:26

All right. Great. Sounds exciting. Thanks for taking my questions.

Fredrik Alpsten
43:27 - 43:28

Thank you.

Operator
43:33 - 43:57

As a reminder, if you wish to ask a question, please dial the Pound Key and then 5 on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any written questions and closing comments.

Fredrik Alpsten
43:58 - 44:14

On this earnings call, even if it's holiday time for most people in Scandinavia, I hope you will have a nice holiday and let's get in touch later in the fall when we have our third earnings call for this year. Thank your.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…